Straits Times Index
3,330.01 -8.93 (-0.27%) S&P 500
5,347.09 +55.75 (+1.05%) Dow
38,809.02 +97.73 (+0.25%) Nasdaq
17,153.04 +295.99 (+1.76%) Bitcoin USD
71,105.83 +451.23 (+0.64%) CMC Crypto 200
1,519.97 +46.23 (+3.14%)
Daiichi Sankyo Company, Limited (D4S.F)
| Previous close | 31.81 |
| Open | 32.38 |
| Bid | 32.39 x 50000 |
| Ask | 33.36 x 50000 |
| Day's range | 32.38 - 32.38 |
| 52-week range | 22.35 - 34.48 |
| Volume | |
| Avg. volume | 99 |
| Market cap | 62.301B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 53.08 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.36 (1.14%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- Business Wire
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
TOKYO & BASKING RIDGE, N.J., June 02, 2024--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy
- PR Newswire
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. Both rilvegostomi
- Business Wire
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., May 27, 2024--Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. Survival results did not reach statistical signific
